0004

Pacific Shuanglin Bio-pharmacy Co., LTD 000403

Market Closed
18 Jul, 06:57
XSHE XSHE
¥
27. 36
+0.91
+3.44%
¥
19.68B Market Cap
35.38 P/E Ratio
0.2% Div Yield
6,310,474 Volume
0.77 Eps
¥ 26.45
Previous Close
Day Range
26.1 27.87
Year Range
17.49 31.25

000403 Chart

Pacific Shuanglin Bio-pharmacy Co., LTD Profile

Biotechnology Industry
Healthcare Sector
Mr. Hua Gang Yuan CEO
XSHE Exchange
CNE000000F14 ISIN
CN Country
2,426 Employees
- Last Dividend
27 Jul 2020 Last Split
7 Jun 1996 IPO Date

Overview

Pacific Shuanglin Bio-pharmacy Co., Ltd. stands as a significant entity in the biopharmaceutical field within China, focusing on the research, development, production, and sales of blood products. The company, rooted in its mission to contribute to healthcare and medicine, offers a range of essential blood-derived medical solutions. Originally known as Southern Shuanglin Bio-pharmacy Co., Ltd., it underwent a name change to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021, marking a new chapter in its commitment to lifesaving biopharmaceuticals. Founded in 1993 and based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy has expanded its expertise beyond blood products to include investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects, alongside electronic product information consultation. This expansion underscores its vision to be at the forefront of the biotechnology and pharmaceutical industries, not just in China, but globally.

Products and Services

Pacific Shuanglin Bio-pharmacy Co., Ltd. offers a diverse portfolio of products and services dedicated to improving human health and combating diseases through biotechnological advancements. Their product lineup includes, but is not limited to:

  • Human Serum Albumin: A vital blood plasma protein used in treating various conditions such as burns, shock, and blood loss, making it invaluable in emergency and surgical medicine.
  • Human Immunoglobulin: Used in immunotherapy, this product provides essential antibodies to individuals lacking them, thereby preventing infections and treating diseases where the immune system is compromised.
  • Intravenous Human Immunoglobulin (PH4): Specifically designed for intravenous administration, this product is crucial for treating conditions that require immediate immune system support, including severe infections and immune disorders.
  • Hepatitis B Human Immunoglobulin: Tailored for the prevention and treatment of hepatitis B, this product provides immediate immunity to individuals exposed to the hepatitis B virus, reducing the risk of contracting the disease.
  • Tetanus Human Immunoglobulin: This is deployed in the prevention and treatment of tetanus, offering immediate immunity to individuals potentially exposed to the tetanus toxin.
  • Rabies Patient Immunoglobulin: Used as part of post-exposure prophylaxis, this product provides passive immunity to individuals exposed to the rabies virus, a crucial step in preventing the onset of this deadly disease.
  • Human Coagulation Factor: Aimed at treating and managing bleeding disorders such as hemophilia, this product aids in the normal blood clotting process, providing relief and prevention of bleeding episodes in affected individuals.

In addition to its core product offerings, Pacific Shuanglin Bio-pharmacy is actively involved in the investment, consultation, and promotion of pharmaceutical and biotechnology development projects, underscoring its commitment to fostering innovation and excellence in the biopharmaceutical industry.

Contact Information

Address: Sunshine City Global Financial Center, Taiyuan, China
Phone: -